NU-9 Is Now AKV9, and Doing Well in Preclinical Studies

AKAVA Therapeutics’ experimental therapy AKV9, formerly NU-9, was superior to approved therapies for amyotrophic lateral sclerosis (ALS) at improving the health of lab-grown upper motor neurons from a mouse model of the disease, a study shows. Upper motor neurons are one of the two types of specialized nerve cells that…

Mutations in FUS Gene Affects Growth and Workings of Motor Neuron Axons, Study Shows

Mutations in the FUS gene, one of the most common causes of familial amyotrophic lateral sclerosis (ALS), increase the number of branches extending from the axons of motor nerve cells, so that no clear path exists for these neuronal “arms” to transmit information — in the form of electrical impulses —…